Transfusion and COVID-19 (TRANSCOV-19)

November 18, 2021 updated by: University Hospital, Strasbourg, France

Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure.

To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
        • Contact:
        • Sub-Investigator:
          • François LEVY, MD
        • Sub-Investigator:
          • Xavier Delabranche, MD
        • Sub-Investigator:
          • Charles TACQUARD, MD
        • Sub-Investigator:
          • Françoise BERTRAND, MD
        • Sub-Investigator:
          • Christian GACHET, MD
        • Sub-Investigator:
          • Catherine HUMBRECHT, MD
        • Sub-Investigator:
          • Daniel KIENTZ, MD
        • Sub-Investigator:
          • Pierre TRAN BA LOC, MD
        • Sub-Investigator:
          • Xavier PIVOT, MD
        • Sub-Investigator:
          • Florian SIRLIN, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients (≥18 years old) admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020

Description

Inclusion criteria:

  • Adults patient (≥18 years old)
  • Patients admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020
  • Labile blood products consumed between February 24 and May 31 of 2019 and 2020
  • Subjects not having his opposition, after information, to the reuse of his data for the purposes of this research.

Non-inclusion criteria:

  • Patients who expressed opposition to participating in the study
  • Patients under legal protection
  • Patients under guardianship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020
Time Frame: Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]
Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Investigators

  • Principal Investigator: Paul-Michel MERTES, MD, PhD, Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Anticipated)

December 31, 2021

Study Completion (Anticipated)

December 31, 2021

Study Registration Dates

First Submitted

October 11, 2021

First Submitted That Met QC Criteria

October 11, 2021

First Posted (Actual)

October 13, 2021

Study Record Updates

Last Update Posted (Actual)

December 1, 2021

Last Update Submitted That Met QC Criteria

November 18, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7958 (CTEP)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe